drugset / Trial / NCT00004327

Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia

NCT00004327

Treatment

Summary

OBJECTIVES: I. Evaluate the efficacy of octreotide, a somatostatin octapeptide analog, in decreasing gastrointestinal bleeding in patients with hormone-refractory hereditary hemorrhagic telangiectasia or senile ectasia.

Timeline

Start
1995-01
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide Subcutaneous